title: Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days).
abstract: BACKGROUND
  Current guidelines on the management of urinary tract infection recommend treating febrile urinary tract infection or acute pyelonephritis with antimicrobials for at least 14 days. Few randomized trials showed the effectiveness of treatment durations of 5 to 7 days but this has only been studied in young previously healthy women.
  
  
  METHODS
  A randomized placebo-controlled double-blind multicenter non-inferiority trial in which 400 patients with community acquired febrile urinary tract infection will be randomly allocated to a short treatment arm (7 days of ciprofloxacin or 7 days of empirical beta-lactams +/- gentamicin intravenously with early switch to oral ciprofloxacin followed by 7 days of blinded placebo) or standard treatment arm (7 days of ciprofloxacin or 7 days of empirical beta-lactams +/- gentamicin intravenously with early switch to oral ciprofloxacin followed by 7 days of blinded ciprofloxacin). The study is performed in the Leiden region in which one university hospital, 6 general hospitals and 32 primary health care centers are clustered. Patients eligible for randomization are competent patients aged 18 years or above with a presumptive diagnosis of acute pyelonephritis as defined by the combination of fever, one or more symptoms of urinary tract infection and a positive urine nitrate test and/or the presence of leucocyturia. Exclusion criteria are known allergy to fluoroquinolones, female patients who are pregnant or lactating, polycystic kidney disease, permanent renal replacement therapy, kidney transplantation, isolation of ciprofloxacin-resistant causal uropathogen, renal abscess, underlying chronic bacterial prostatitis, metastatic infectious foci and inability to obtain follow-up. The primary endpoint is the clinical cure rate through the 10- to 18-day post-treatment visit. Secondary endpoints are the microbiological cure rate 10- to 18-day post-treatment, the 30- and 90-day overall mortality rate, the clinical cure rate 70- to 84-day post-treatment, relapse rate of UTI and adverse events or complications during 90 days of follow-up.
  
  
  CONCLUSIONS
  This study aims to demonstrate that 7 days of antimicrobial treatment is non-inferior as compared with 14 days of treatment in patients with febrile urinary tract infection. In addition, it will generate insights into the side-effects of antimicrobial treatment in relation to its duration. The study population will also include men, the elderly and patients with significant co-morbidity. Reflecting daily practice of primary health care and emergency departments, the results of this study can be generalized to other locations.
authors.affiliation: Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands. c.van_nieuwkoop@lumc.nl
authors.forename: Cees
authors.initials: C
authors.lastname: van Nieuwkoop
authors.forename: Jan W
authors.initials: JW
authors.lastname: van't Wout
authors.forename: Willem J J
authors.initials: WJ
authors.lastname: Assendelft
authors.forename: Henk W
authors.initials: HW
authors.lastname: Elzevier
authors.forename: Eliane M S
authors.initials: EM
authors.lastname: Leyten
authors.forename: Ted
authors.initials: T
authors.lastname: Koster
authors.forename: G Hanke
authors.initials: GH
authors.lastname: Wattel-Louis
authors.forename: Nathalie M
authors.initials: NM
authors.lastname: Delfos
authors.forename: Hans C
authors.initials: HC
authors.lastname: Ablij
authors.forename: Ed J
authors.initials: EJ
authors.lastname: Kuijper
authors.forename: Jan
authors.initials: J
authors.lastname: Pander
authors.forename: Jeanet W
authors.initials: JW
authors.lastname: Blom
authors.forename: Ida C
authors.initials: IC
authors.lastname: Spelt
authors.forename: Jaap T
authors.initials: JT
authors.lastname: van Dissel
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D005334:Fever / Q000188:drug therapy*; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D008297:Male; D014552:Urinary Tract Infections / Q000188:drug therapy*; D047090:beta-Lactams / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D005839:Gentamicins; D047090:beta-Lactams; D002939:Ciprofloxacin
references.citation: Eur Urol. 2001 Nov;40(5):576-88
references.pmid: 11752870
references.citation: Int J Antimicrob Agents. 1999 May;11(3-4):189-96; discussion 213-6
references.pmid: 10394969
references.citation: Ann Epidemiol. 2003 Feb;13(2):144-50
references.pmid: 12559674
references.citation: Ann Pharmacother. 2007 Nov;41(11):1859-66
references.pmid: 17911203
references.citation: Am J Emerg Med. 1997 Mar;15(2):148-51
references.pmid: 9115515
references.citation: J Urol. 2004 Feb;171(2 Pt 1):734-9
references.pmid: 14713799
references.citation: Clin Ther. 2002 Feb;24(2):223-36
references.pmid: 11911553
references.citation: Int J Antimicrob Agents. 2004 Mar;23 Suppl 1:S41-53
references.pmid: 15037328
references.citation: Int J Antimicrob Agents. 2008 Feb;31 Suppl 1:S40-5
references.pmid: 18023152
references.citation: JAMA. 2003 Sep 24;290(12):1624-32
references.pmid: 14506122
references.citation: Eur J Clin Microbiol Infect Dis. 1990 May;9(5):317-23
references.pmid: 2197091
references.citation: Ann Intern Med. 1987 Mar;106(3):341-5
references.pmid: 3492950
references.citation: Int J Antimicrob Agents. 2006 Aug;28 Suppl 1:S49-63
references.pmid: 16854569
references.citation: Arch Intern Med. 1999 Jan 11;159(1):53-8
references.pmid: 9892331
references.citation: Stat Med. 2003 Jan 30;22(2):169-86
references.pmid: 12520555
references.citation: Am Fam Physician. 2005 Mar 1;71(5):933-42
references.pmid: 15768623
references.citation: Infect Dis Clin North Am. 2003 Jun;17(2):333-51
references.pmid: 12848473
references.citation: Curr Med Res Opin. 2007 Nov;23(11):2637-45
references.pmid: 17880755
references.citation: Scand J Infect Dis. 2003;35(1):34-9
references.pmid: 12685882
references.citation: Infect Dis Clin North Am. 2003 Jun;17(2):303-32
references.pmid: 12848472
references.citation: Arch Intern Med. 2003 Oct 27;163(19):2393; author reply 2393-4
references.pmid: 14581259
references.citation: Pharmacoeconomics. 2005;23(11):1123-42
references.pmid: 16277548
references.citation: Urology. 2008 Jan;71(1):17-22
references.pmid: 18242357
references.citation: Clin Infect Dis. 2007 Aug 1;45(3):273-80
references.pmid: 17599303
references.citation: N Engl J Med. 2006 Oct 19;355(16):1690-8
references.pmid: 17050893
references.citation: Clin Infect Dis. 1999 Oct;29(4):745-58
references.pmid: 10589881
references.citation: JAMA. 2000 Mar 22-29;283(12):1583-90
references.pmid: 10735395
references.citation: Obstet Gynecol. 2008 Mar;111(3):785-94
references.pmid: 18310389
references.citation: Clin Infect Dis. 1996 Jun;22(6):1051-6
references.pmid: 8783709
references.citation: Clin Infect Dis. 1992 Nov;15 Suppl 1:S216-27
references.pmid: 1477233
references.citation: Curr Med Res Opin. 2007 Jun;23(6):1403-13
references.pmid: 17559736
references.citation: JAMA. 2006 Mar 8;295(10):1152-60
references.pmid: 16522836
references.citation: BMJ. 2008 Nov 11;337:a2390
references.pmid: 19001484